ESC Premium Access

The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.

Congress Presentation

About the speaker

Doctor Spyridon Maragkoudakis

General Hospital St. George, Chania (Greece)
0 follower

8 more presentations in this session

Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis

Speaker: Mr B. Tan (Singapore, SG)

Thumbnail

The effect of metformin use on the risk of atrial fibrillation in patients with type 2 diabetes: data from the UK biobank

Speaker: Doctor T. Guo (Xi'an, CN)

Thumbnail

All cause mortality in people with type 2 diabetes using SGLT-2 inhibitors compared to DPP4 inhibitors using the danish registries

Speaker: Doctor P. Yazdanfard (Hilleroed, DK)

Thumbnail

Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report.

Speaker: Doctor M. Feola (Mondovi, IT)

Thumbnail

Identification and optimisation of a risk stratified cohort of patients with type 2 diabetes through the delivery of a enhanced pharmacist-led service

Speaker: Mr S. Mcbrien (Belfast, GB)

Thumbnail

Access the full session

Real-world evidence on the cardiovascular effects of therapies for diabetes

Speakers: Doctor S. Maragkoudakis, Mr B. Tan, Doctor T. Guo, Doctor P. Yazdanfard, Doctor M. Feola...
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations